Skip to main content

Table 2 Possible molecular targets for therapy in SSc

From: Molecular targets for therapy in systemic sclerosis

Target molecules Available drug name References
Tyrosine kinases Imatinib, Nilotinib, Dasatinib Iwamoto N et al.
Curr Rheumatol Rep.
2011;13:21
SRC kinases SU6656, Dasatinib Akhmetshina A et al.
FASEB J.
2008;22:2214
TGF-b inhibitors Several drugs Asano Y.
J Dermatol
2010;37:54
Histondeacetylase inhibitor Trichostatin, SAHA Huber LC et al.
Arthritis Rheum
2007;56:2755
DNA Methyltransferase inhibitors 5-AZA Wang Y et al.
Arthritis Rheum
2006;54:2271
Rho associated kinase Fasudil Akhmetshina A et al.
Arthritis Rheum
2008;58:2553
Cannabinoid receptor 2 (CB2) agonists Several drugs Akhmetshina A et al.
Arthritis Rheum.
2009;60:1129
PPAR γ agonists None Wei J et al.
PloS One
2010;5:e13778
Adenosine A2A receptor blockers None Chan ES et al.
Arthritis Rheum.
2006;54:2632
IL-13 inhibitors None Lafyatis R et al.
Endocr Metab Immune Disord Targets
2006;6:395
Serotonin-Receptor-2B inhibitors Terguride Dees C et al.
J Exp Med.
2011; 208:961
CTGF inhibitor CTGF antibodies Wang Q et al.
Fibrogenesis Tissue Repair
2011;4:4
IL-6 receptor antagonist Tocilizmab Shima Y et al.
Rheumatology(oxford)
2010;49:2408
MicroRNA-29a None Maurer B et al.
Arthritis Rheum
2010;62:1733
Fos-Related Antigen-2 (AP-1 family) None Reich N et al.
Arthritis Rheum
2010;62:280
Maurer B et al.
Circulation.
2009;120:2367